Autres langues AstraZeneca PLC Xetra

Actions

ZEG

GB0009895292

Produits pharmaceutiques

Temps réel estimé Tradegate 22:00:01 20/08/2026			Varia. 5j.	Varia. 1 janv.
140,85 ^EUR	-12,35%		0,00%	+1,81%

16:32	Le secteur pharmaceutique mise massivement sur l'IA dans l'espoir de réduire les coûts et les délais	RE
15:59	Les vaccins contre le cancer enfin sous le feu des projecteurs

Autres langues

16:32	Pharma sector doubles down on AI amid hopes of slashing costs, timelines
15:59	Cancer vaccines finally garner the spotlight
15:52	Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner
10:37	Goldman likes Astra; JPMorgan lowers Trainline
09:00	JD cuts guidance; Standard Life expands UK pensions
19/08	WINNERS & LOSERS: Trainline hit by CMA probe; Smith & Nephew CFO exits
18/08	FTSE 100 holds modest gains as Brent tops USD90
18/08	European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
18/08	AstraZeneca - Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer
18/08	AstraZeneca - Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer
18/08	Oil surge, pound slip aids FTSE 100 but peers fall
17/08	Health Care Down on Growth Doubts - Health Care Roundup
17/08	FTSE 100 falls for sixth day in a row as consumer stocks weigh
17/08	UK Shares Start Week Downbeat; AstraZeneca Shares Data from Lung Cancer Trials
17/08	European Stocks Close Lower in Monday Trading Despite Tech, Mining Stocks Rally
17/08	BofA Notes AstraZeneca's Volrustomig Late-stage Study Fail; Buy Maintained
17/08	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
17/08	TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
17/08	AstraZeneca Demonstrates Statistically Significant and Clinically Meaningful Improvements with TAGRISSO Plus Savolitinib in Saffron Phase III Trial
17/08	FTSE 100 set to snap six-day losing streak as miners gain
17/08	AstraZeneca Discontinues EVOLVE-Lung02 Phase III Trial Of Volrustomig Plus Chemotherapy In Metastatic Non-Small Cell Lung Cancer
17/08	HUTCHMED Announces ORPATHYS plus TAGRISSO Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer
17/08	AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review -- Update
17/08	European Midday Briefing : Shares Mixed as Iran Ceasefire Set to Expire
17/08	Hong Kong Stocks Rise on Monday on Tech Gains; Alibaba Rises 2%